Project Grant R44CA281528

Award Date 9/25/23
Completion Date 8/30/25
Dollars Obligated $2.9M
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to Electronic Biosciences, Inc., a small biotechnology company in San Diego, CA. The funding will support the development of a novel nanopore-based sequencing approach to accurately characterize repetitive DNA sequences, which are challenging to analyze using current sequencing-by-synthesis technology. This capability will enable improved cancer...
The National Cancer Institute (NCI) awarded a $601,364 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Data Driven Bioscience Inc. for the project "Clinical Validation of DuoSeq, a Swiss Army Knife Genomic Approach to Diagnosis of Blood Cancers." The funding supports the analytical and clinical validation of extended applications for the DuoSeq assay, a novel approach that enables simultaneous DNA and RNA sequencing from a single workflow to...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will fund the development of a novel technology for spatially resolved multi-omics sequencing of formalin-fixed paraffin-embedded (FFPE) tumor tissue samples at the cellular level. The $227,906 award, effective from September 17, 2024 to August 31, 2027, will enable the researchers at The Trustees of the University of Pennsylvania to (1) develop spatial epigenome sequencing to measure gene...
This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), supports the development of an innovative platform called CytopeDrop by Survey Genomics, Inc. CytopeDrop enables high-throughput, spatially-resolved multiomics analysis at the single-cell level, integrating measurements of mRNA abundance, protein expression, and cell location. The $1,887,931 award, with a project period from September 2024 to...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $679,188 to The Regents of the University of California, San Francisco to develop liquid biopsy tools for detecting and profiling malignant effusions associated with metastatic breast cancer. The key objectives are to: 1) Validate an AI-assisted, morphology-based platform to isolate circulating tumor cells from malignant effusions; 2) Perform molecular characterization...
This $339,300 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports Triangle Biotechnology's development of a nanodroplet-enhanced sonication technology called ChromExtract. The goal is to enable high-quality, high-yield, and consistent chromatin extraction from formalin-fixed, paraffin-embedded (FFPE) tissue samples for downstream chromatin profiling and accessibility analyses. The...
This $440,287 federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to establish a simplified and accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. The objective is to democratize cancer biobanking by enabling smaller and lower-resource institutes to participate, addressing the current underrepresentation of samples from non-white patient populations. The project will optimize...
This National Cancer Institute Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" will develop and validate a multi-stage, multi-modal biomarker to predict the risk of progression from oral premalignant lesions (OPLs) to oral cavity squamous cell carcinoma (OSCC). The project, titled "PROSPECT: Premalignant Oral Lesions Pathology and Epigenetic Risk Prediction Tool," will use a combination of cytology, histology, and epigenomics to create a risk...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports the development and optimization of a novel single-cell multi-omic profiling method called SHARE-ME-SEQ. The $237,023 award will enable the Icahn School of Medicine at Mount Sinai to create a scalable and cost-effective technique to simultaneously capture gene expression, chromatin accessibility, and DNA methylation data at the single-cell level. The goal is to apply this method...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $678,228 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop GLISCAN, a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The project aims to optimize, verify, and validate GLISCAN in adherence with industry standards, with the intention of...

CHROMOSOMAL ABERRATION DETECTION IN FFPE TISSUE USING PROXIMITY LIGATION SEQUENCING - ABSTRACT THE DETECTION OF CHROMOSOMAL ABERRATIONS IS A FRONTLINE DIAGNOSTIC FOR THE SPECTRUM OF BLOOD NEOPLASMS. CHROMOSOMAL ABERRATIONS, SUCH AS TRANSLOCATIONS, INVERSIONS, DELETIONS AND INSERTIONS, HAVE BEEN HISTORICALLY IDENTIFIED USING CYTOGENETIC METHODS OR MORE RECENTLY THROUGH APPLICATION OF LONG READ SEQUENCING OR OPTICAL MAPPING TECHNOLOGIES. THESE METHODS HAVE BEEN LESS APPLICABLE IN SOLID TUMOR RESEARCH AND DIAGNOSTICS BECAUSE THEY REQUIRE EITHER VIABLE CELLS OR HIGH-MOLECULAR WEIGHT DNA. THE VAST MAJORITY OF SOLID TUMOR BIOPSIES ARE STORED IN FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPE) BLOCKS, A PROCESS THAT HIGHLY FRAGMENTS GENOMIC DNA. IN THIS PROPOSAL WE DESCRIBE A LOW-COST AND SCALABLE METHOD COMPATIBLE WITH FFPE TISSUE THAT ENABLES THE DETECTION OF CHROMOSOMAL ABERRATION USING PROXIMITY LIGATION SEQUENCING. PROXIMITY LIGATION METHODS SUCH AS CHROMOSOME CONFORMATION CAPTURE (3C) AND HI-C CAN BE USED TO ORDER AND ORIENT SEGMENTS OF GENOMES, RECONSTRUCTING END-TO-END CHROMOSOME SEQUENCES. WHEN A SEQUENCE DEVIATES FROM THE EXPECTED ORDER OR ORIENTATION, SUCH AS IS IN THE CASE OF CHROMOSOMAL ABERRATIONS, THE SEQUENCE APPEARS AS AN OBVIOUS OFF-DIAGONAL SIGNAL ON A HI-C HEATMAP, MAKING IDENTIFICATION OF CHROMOSOMAL ABNORMALITIES AN AUTOMATABLE PROCESS. WE PROPOSE TO APPLY PROXIMITY LIGATION AS A CYTOGENOMIC METHOD TO DETECT THE BREADTH OF CHROMOSOMAL ABERRATIONS AT HIGH RESOLUTION AND LOW COST. THIS PROPOSAL OUTLINES A PATH TO A COMMERCIALLY AVAILABLE PRODUCT AND SERVICE, WHICH WILL ESTABLISH A HIGHLY VALIDATED METHOD FOR USE IN RESEARCH AND EVENTUALLY IN A DIAGNOSTIC SETTING. THIS WILL BE ACCOMPLISHED BY 1) DESIGNING AN EASY TO USE FFPE HI-C PROTOCOL AMENABLE TO MULTIWELL PLATE HANDLING, 2) BUILDING A ROBUST AUTOMATED PLATFORM TO REPRODUCIBLY CALL CHROMOSOME ABERRATIONS FROM HI-C DATA, AND 3) PROVING THE VALIDITY AND REPRODUCIBILITY OF THESE METHODS ON REAL WORLD SAMPLE. THE RESULT OF THESE EFFORTS WILL BE A NEW CANCER CYTOGENETICS METHODOLOGY CALLED KARYOTYPING BY SEQUENCINGTM (KBS).

Posted 9/25/23, 12:00 AM